|Day Low/High||286.68 / 297.64|
|52 Wk Low/High||271.57 / 442.00|
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
* First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP)
These bearish bets are showing both technical and quantitative deterioration.
REGN, NOMD, LMNR, MOV and HTHT all recently were downgraded by TheStreet's Quant Ratings.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: SCM, UFCS Downgrades: GCO, GIII, JE, KR, MLAB, OCC, PK, REGN, TAIT, WMK Initiations: HMI, PVTL, SMAR Read on to get TheStreet Quant Ratings' detailed report:
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.